Last reviewed · How we verify
Post-essential thrombocythaemia myelofibrosis
Approved treatments
- Inrebic · Bristol-Myers Squibb
Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs. - Inrebic · Bristol-Myers Squibb
Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Post-essential thrombocythaemia myelofibrosis patent landscape — cliff calendar, originator estates, attackable patents
- Post-essential thrombocythaemia myelofibrosis treatment landscape brief
- Post-essential thrombocythaemia myelofibrosis treatment updates RSS
Frequently asked questions about Post-essential thrombocythaemia myelofibrosis
What drugs treat Post-essential thrombocythaemia myelofibrosis?
Tracked treatments include Inrebic.
What is the treatment for Post-essential thrombocythaemia myelofibrosis?
Standard treatment for Post-essential thrombocythaemia myelofibrosis includes Inrebic. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Post-essential thrombocythaemia myelofibrosis patent cliff · Post-essential thrombocythaemia myelofibrosis CI report
- Treatment: Inrebic · Bristol-Myers Squibb
- Treatment: Inrebic · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing